Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Memory cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    139 result(s) found for: Memory cells. Displaying page 4 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2015-000827-94 Sponsor Protocol Number: U-DANCE-anti-AML Start Date*: 2016-09-08
    Sponsor Name:UMC Utrecht
    Full Title: A phase I/II post cord blood HCT dendritic cells vaccination trial directed against WT1 for pediatric acute myeloid leukemia: the U-DANCE-anti-AML trial
    Medical condition: AML: Acute Myeloid leukemia/ cancer of blood and bone marrow
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    19.0 100000004864 10000887 Acute myeloid leukemia in remission LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2019-001789-13 Sponsor Protocol Number: 2016/02 Start Date*: 2020-01-13
    Sponsor Name:Clinical Trials and Research Governance (CTRG), University of Oxford
    Full Title: A randomised, open label study, exploring the differences in immunogenicity and reactogenicity of infants after immunisation with either an acellular (aP) or whole cell pertussis (wP) vaccine
    Medical condition: This study is going to focus on the immunisations against pertussis disease in previous healthy children, but the disease itself is not going to be study.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10034738 Pertussis PT
    21.1 10021881 - Infections and infestations 10047976 Whooping cough due to bordetella pertussis (B. pertussis) LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-000089-11 Sponsor Protocol Number: AX-CL-09 Start Date*: 2004-12-15
    Sponsor Name:Axonyx Inc
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease
    Medical condition: Alzheimer's Disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimer's also affects the levels of a certain neu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003240-25 Sponsor Protocol Number: FIBHGM-ECNC003-2021 Start Date*: 2023-06-01
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Gregorio Marañón
    Full Title: PHASE I/IIa OPEN CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ALLOGENIC ADMINISTRATION OF TREG CELLS OBTAINED FROM THYMAL TISSUE (thyTreg) IN THE CONTROL OF IMMUNOLOGICAL HYPERACTIVATION ...
    Medical condition: immune hyperactivation in COVID-19 patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010516-15 Sponsor Protocol Number: 3227K1-2000-WW Start Date*: 2009-08-14
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: Randomized, Parallel, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis on a Stable Background of Metho...
    Medical condition: Rheumatoid arthritis (seropositive)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040107 Seropositive rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002567-24 Sponsor Protocol Number: M120204-063 Start Date*: 2005-04-04
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis
    Medical condition: The purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-015113-44 Sponsor Protocol Number: NEAT001 Start Date*: 2010-05-19
    Sponsor Name:ANSR
    Full Title: Ensayo abierto, aleatorizado, de dos años de duración, en el que se comparan dos regímenes de primera línea en sujetos infectados por el VIH que no han recibido tratamiento antirretroviral previo: ...
    Medical condition: Infección por el virus de la inmunodeficiencia humana
    Disease: Version SOC Term Classification Code Term Level
    11 10068341 Infección por VIH 1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) SE (Completed) IE (Completed) DK (Completed) PT (Completed) AT (Completed) DE (Completed) GB (Completed) PL (Completed) IT (Completed) BE (Completed) NL (Completed) HU (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002876-26 Sponsor Protocol Number: 2017-002876-26 Start Date*: 2018-10-19
    Sponsor Name:South Tees Hospitals NHS Foundation Trust
    Full Title: Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome: a double-blind, phase II, pilot randomised controlled trial (TACTIC)
    Medical condition: Immunosenescence in patients who have had an acute coronary syndrome diagnosed within the last 6 months.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10011968 Decreased immune responsiveness PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000673-68 Sponsor Protocol Number: 16IC17 Start Date*: 2018-10-09
    Sponsor Name:Great Ormond Street Hospital for Children NHS Trust
    Full Title: Phase I/II study of lentiviral gene transfer for SCID-X1 with low dose targeted busulfan
    Medical condition: Severe combined immunodeficiency disorder (SCID) is a heterogeneous group of inherited disorders characterized by a profound reduction or absence of T lymphocyte function, resulting in lack of both...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10069566 Severe combined immunodeficiency syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001925-15 Sponsor Protocol Number: ISS20159321 Start Date*: 2018-10-22
    Sponsor Name:Alcedis GmbH
    Full Title: Evaluation of immunological effects of the RANKL-inhibitor Denosumab when administered concurrently with PD1-blocking antibodies (Nivolumab, Pembrolizumab) in patients with metastatic malignant me...
    Medical condition: Metastatic malignant melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002145-63 Sponsor Protocol Number: INMiND-02 Start Date*: 2015-10-15
    Sponsor Name:University of Southampton
    Full Title: A double-blind, placebo-controlled study of the effect of a TNF alpha inhibitor, etanercept (Enbrel), on microglial activation in amyloid PET positive patients with Mild Cognitive Impairment due to...
    Medical condition: Mild Cognitive impairment- due to Alzheimer's disease- intermediate likelihood
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003563-36 Sponsor Protocol Number: ACQUIVAS Start Date*: 2018-07-30
    Sponsor Name:Cambridge University Hospital NHS Foundation Trust and University of Cambridge
    Full Title: ACQUIVAS - Acquired immunodeficiency in ANCA associated vasculitis (AAV)
    Medical condition: Pneumococcal vaccine responses in ANCA associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004883-23 Sponsor Protocol Number: APHP191116 Start Date*: 2020-10-06
    Sponsor Name:APHP
    Full Title: A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adu...
    Medical condition: Adult patients (n=10) requiring an allogeneic HSCT for the treatment of AML with an unfavorable prognosis according to international criteria in first complete remission or second complete remissio...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000881 Acute myeloid leukaemia (in remission) PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000933-12 Sponsor Protocol Number: AX-CL-10 Start Date*: 2005-02-22
    Sponsor Name:Axonyx Inc
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease
    Medical condition: Alzheimers disease is caused by a loss of nerve cells in the brain, particularly in the areas associated with memory and learning. The onset of Alzheimers's also affects the levels of a certain neu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002589-38 Sponsor Protocol Number: HBV-2013 Start Date*: 2013-07-11
    Sponsor Name:Universität Innsbruck, Institut für Biomedizinische Alternsforschung
    Full Title: Primary and booster vaccination in old age: Hepatitis A and Hepatitis B
    Medical condition: This study will analyze cellular and humoral immune reponses after primary or booster vaccination against HAV and HBV. Healthy adults will be vaccinated with a combination vaccine, which is license...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10054181 Hepatitis B immunization LLT
    16.1 100000004865 10063436 Hepatitis A immunization LLT
    16.1 100000004865 10068384 Hepatitis immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001336-22 Sponsor Protocol Number: AX-PC-201 Start Date*: 2004-11-03
    Sponsor Name:Axonyx Inc.
    Full Title: Effect of Phenserine Treatment on Amyloid in Brains of Patients with Mild Probable Alzheimer’s Disease as studied by Positron Emission Tomography (PET). A Randomised, three Months Double-Blind, Pla...
    Medical condition: Alzheimer’s Disease (AD) is the most common disease leading to dementia and it affects approximately 4 to 8% of the population aged above 65 years. The disease incidence is closely correlated with ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003236-30 Sponsor Protocol Number: 104887 Start Date*: 2006-09-18
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults previously vac...
    Medical condition: Immunisation against influenza disease in an elderly population aged over 65 years
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008195-13 Sponsor Protocol Number: 2008-008195-13 Start Date*: 2009-02-18
    Sponsor Name:Swedish Institute for Infectious Disease Control (SMI)
    Full Title: An immunogenicity and safety study of combined adsorbed tetanus, low dose diphtheria and acellular pertussis vaccine (Td5ap and Td1aP) given as a school-leaving booster to 14-15-year-old children p...
    Medical condition: Two vaccines against diphtheria, tetanus and pertussis will be tested and immune respons investigated in 14-15-year-old children primed with a five component acellular pertussis vaccine at 3, 5 and...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003243-21 Sponsor Protocol Number: TRANSGRIPE 1-2 Start Date*: 2011-10-17
    Sponsor Name:Fundación Pública Andaluza Progreso y Salud
    Full Title: Randomized, comparative and prospective clinical trial evaluating efficacy and safety of a dose of seasonal flu vaccine compared to two doses of vaccine for prevention of influenza in solid organ t...
    Medical condition: seasonal influenza prophylaxis in trasplant receipiens
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10021829 Infection in solid organ transplant recipients LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000930-32 Sponsor Protocol Number: SJ2021005 Start Date*: 2021-04-27
    Sponsor Name:AZ Sint-Jan Brugge-Oostende AV
    Full Title: COVID-19: Documentation of humoral and cellular immune response of hemodialysis patients after vaccination against SARS-CoV-2
    Medical condition: hemodialysis patients hemodialysis patients with comorbidities
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 11:14:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA